Neo Performance Materials Analysts Significantly Upgrade Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy NEO?
Source: Yahoo Finance
- Revenue Upgrade: Analysts have raised Neo Performance Materials' 2026 revenue forecast from $526 million to $587 million, reflecting a significant 15% increase that indicates a substantial enhancement in the company's sales capabilities, potentially driving the stock price higher.
- Earnings Improvement: The expected earnings per share for 2026 is now projected at $0.50, up from the previous estimate of $0.48, demonstrating an increase in the company's profitability and boosting investor confidence.
- Price Target Increase: Analysts have lifted the price target by 32% to $27.15, with the most optimistic analyst setting a target of $30.25 and the most pessimistic at $22.64, indicating a strong consensus on the company's value due to the tight range of estimates.
- Industry Growth Comparison: Neo Performance Materials is forecasted to achieve a 20% annual growth rate moving forward, significantly better than the 1.4% decline over the past five years and exceeding the broader industry’s expected 1.8% annual growth, highlighting the company's competitive advantage in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 8.360
Low
12.00
Averages
14.00
High
16.00
Current: 8.360
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neo Performance Materials Analysts Significantly Upgrade Revenue Estimates
- Revenue Upgrade: Analysts have raised Neo Performance Materials' 2026 revenue forecast from $526 million to $587 million, reflecting a significant 15% increase that indicates a substantial enhancement in the company's sales capabilities, potentially driving the stock price higher.
- Earnings Improvement: The expected earnings per share for 2026 is now projected at $0.50, up from the previous estimate of $0.48, demonstrating an increase in the company's profitability and boosting investor confidence.
- Price Target Increase: Analysts have lifted the price target by 32% to $27.15, with the most optimistic analyst setting a target of $30.25 and the most pessimistic at $22.64, indicating a strong consensus on the company's value due to the tight range of estimates.
- Industry Growth Comparison: Neo Performance Materials is forecasted to achieve a 20% annual growth rate moving forward, significantly better than the 1.4% decline over the past five years and exceeding the broader industry’s expected 1.8% annual growth, highlighting the company's competitive advantage in the market.
See More
NeoGenomics to Participate in Multiple Investor Conferences
- Investor Conference Schedule: NeoGenomics will participate in the 23rd Annual Craig-Hallum Institutional Investor Conference, with 1x1 investor meetings scheduled for May 28, aimed at increasing the company's visibility in the capital markets and attracting potential investors.
- Global Healthcare Conference: The company will also attend the 2026 Jefferies Global Healthcare Conference, with a fireside chat set for June 4 at 10:30 AM EDT, further showcasing its expertise in oncology diagnostics and expected to draw more attention from healthcare investors.
- Webcast and Replay: The webcast of the Jefferies fireside chat will be accessible via the company's website, with an archived replay available, ensuring that investors who cannot attend live can still access the information, thereby enhancing investor relations.
- Company Overview: NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu that serves oncologists, pathologists, and pharmaceutical firms, committed to advancing precision medicine.
See More
NeoGenomics Q1 2026 Earnings Call Insights and Guidance Update
- Significant Revenue Growth: NeoGenomics reported total revenue of $186.7 million for Q1, reflecting an 11% year-over-year increase that exceeded expectations, showcasing the company's strong market performance and growth potential.
- Portfolio Optimization: The five NGS products launched in 2023 contributed 25% of clinical revenue, driving a 26% increase in NGS revenue, which now represents one-third of clinical revenue, indicating a strategic shift towards higher-value offerings.
- Upgraded Full-Year Guidance: Following the MolDX approval of PanTracer Liquid in March, NeoGenomics raised its full-year revenue guidance to a range of $797 million to $803 million, reflecting management's confidence in future performance.
- Market Competitive Advantage: With a 25% market share in diagnostics and therapy selection, the company has enhanced test adoption through the development of over 330 interfaces, which is expected to drive future revenue growth and market share expansion.
See More
NeoGenomics NEO Q2 2025 Earnings Transcript
See More
NeoGenomics Set to Announce Q1 Earnings on April 28
- Earnings Announcement Schedule: NeoGenomics is set to release its Q1 2023 earnings on April 28 after market close, with consensus EPS estimated at $0.00 and revenue expected at $184.48 million, reflecting a 9.8% year-over-year growth.
- Historical Performance Review: Over the past two years, NeoGenomics has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, indicating strong financial performance and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and five downward adjustments, while revenue estimates have experienced no upward revisions and seven downward adjustments, suggesting a cautious market outlook on the company's future performance.
- Future Outlook: NeoGenomics has set a revenue target of $793 million to $801 million for 2026, as initiatives like RaDaR ST and PanTracer gain traction, which is expected to further drive the company's growth.
See More
NeoGenomics Integrates with Epic to Enhance Oncology Testing
- Efficiency Enhancement: NeoGenomics' oncology testing portfolio is now available through the Epic Aura system, allowing physicians to order and view results on the same platform, thereby streamlining the testing process and accelerating clinical decisions.
- Increased Adoption Rates: This integration is expected to drive a 20-30% increase in test adoption rates at hospitals and health systems, facilitating faster treatment initiation for cancer patients and significantly improving treatment timelines.
- Digital Health Strategy Advancement: The integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity between community oncology practices and large health systems, thereby promoting scalable precision oncology adoption.
- Future Diagnostic Capabilities: The
See More
Neo Performance Materials Analysts Significantly Upgrade Revenue Estimates
- Revenue Upgrade: Analysts have raised Neo Performance Materials' 2026 revenue forecast from $526 million to $587 million, reflecting a significant 15% increase that indicates a substantial enhancement in the company's sales capabilities, potentially driving the stock price higher.
- Earnings Improvement: The expected earnings per share for 2026 is now projected at $0.50, up from the previous estimate of $0.48, demonstrating an increase in the company's profitability and boosting investor confidence.
- Price Target Increase: Analysts have lifted the price target by 32% to $27.15, with the most optimistic analyst setting a target of $30.25 and the most pessimistic at $22.64, indicating a strong consensus on the company's value due to the tight range of estimates.
- Industry Growth Comparison: Neo Performance Materials is forecasted to achieve a 20% annual growth rate moving forward, significantly better than the 1.4% decline over the past five years and exceeding the broader industry’s expected 1.8% annual growth, highlighting the company's competitive advantage in the market.
See More
NeoGenomics to Participate in Multiple Investor Conferences
- Investor Conference Schedule: NeoGenomics will participate in the 23rd Annual Craig-Hallum Institutional Investor Conference, with 1x1 investor meetings scheduled for May 28, aimed at increasing the company's visibility in the capital markets and attracting potential investors.
- Global Healthcare Conference: The company will also attend the 2026 Jefferies Global Healthcare Conference, with a fireside chat set for June 4 at 10:30 AM EDT, further showcasing its expertise in oncology diagnostics and expected to draw more attention from healthcare investors.
- Webcast and Replay: The webcast of the Jefferies fireside chat will be accessible via the company's website, with an archived replay available, ensuring that investors who cannot attend live can still access the information, thereby enhancing investor relations.
- Company Overview: NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu that serves oncologists, pathologists, and pharmaceutical firms, committed to advancing precision medicine.
See More
NeoGenomics Q1 2026 Earnings Call Insights and Guidance Update
- Significant Revenue Growth: NeoGenomics reported total revenue of $186.7 million for Q1, reflecting an 11% year-over-year increase that exceeded expectations, showcasing the company's strong market performance and growth potential.
- Portfolio Optimization: The five NGS products launched in 2023 contributed 25% of clinical revenue, driving a 26% increase in NGS revenue, which now represents one-third of clinical revenue, indicating a strategic shift towards higher-value offerings.
- Upgraded Full-Year Guidance: Following the MolDX approval of PanTracer Liquid in March, NeoGenomics raised its full-year revenue guidance to a range of $797 million to $803 million, reflecting management's confidence in future performance.
- Market Competitive Advantage: With a 25% market share in diagnostics and therapy selection, the company has enhanced test adoption through the development of over 330 interfaces, which is expected to drive future revenue growth and market share expansion.
See More
NeoGenomics NEO Q2 2025 Earnings Transcript
See More
NeoGenomics Set to Announce Q1 Earnings on April 28
- Earnings Announcement Schedule: NeoGenomics is set to release its Q1 2023 earnings on April 28 after market close, with consensus EPS estimated at $0.00 and revenue expected at $184.48 million, reflecting a 9.8% year-over-year growth.
- Historical Performance Review: Over the past two years, NeoGenomics has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, indicating strong financial performance and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and five downward adjustments, while revenue estimates have experienced no upward revisions and seven downward adjustments, suggesting a cautious market outlook on the company's future performance.
- Future Outlook: NeoGenomics has set a revenue target of $793 million to $801 million for 2026, as initiatives like RaDaR ST and PanTracer gain traction, which is expected to further drive the company's growth.
See More
NeoGenomics Integrates with Epic to Enhance Oncology Testing
- Efficiency Enhancement: NeoGenomics' oncology testing portfolio is now available through the Epic Aura system, allowing physicians to order and view results on the same platform, thereby streamlining the testing process and accelerating clinical decisions.
- Increased Adoption Rates: This integration is expected to drive a 20-30% increase in test adoption rates at hospitals and health systems, facilitating faster treatment initiation for cancer patients and significantly improving treatment timelines.
- Digital Health Strategy Advancement: The integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity between community oncology practices and large health systems, thereby promoting scalable precision oncology adoption.
- Future Diagnostic Capabilities: The
See More
